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technologies are applied first. Many examples can be named 
easily: cancer stem cell concept, combination chemothera-
pies, flow cytometry, and gene therapy are among those on 
the list. The reason behind such a trend may be the easiness 
of isolation of individual cells exhibiting problems, as well 
as the relative ease of access of the disease for detection and 
intervention compared to other diseases in other fields (such 
as solid tumors and cardiovascular disorders).
For hereditary diseases in hematology, the advance in 
delivery system (particularly, the advance of the viral vec-
tor system) has contributed greatly to the improved clini-
cal outcomes with reduced genotoxicity. Such a trend is 
most evident in ex vivo gene therapy of hereditary diseases, 
and the review by Dr. Tani summarizes recent advances in 
hematological disorders with a special emphasis on global 
comparisons. Another recent game changer has been the 
application of gene editing technologies for the cure of 
human diseases. Zinc finger nucleases, as well as Cas/
CRISPRs and TALENs can be used to edit target genes, 
achieving knock down or repair. These technologies have 
great potential to clinically “destroy” or “repair” the mutant 
gene back to normal without causing genotoxicity in other 
genes. The basic features of gene editing techniques and 
their applications to hematological disorders are reviewed 
by Drs. Osborn, Belanto, Tolar, and Voytas.
On the other hand, the concept of “gene therapy” has 
been expanded to acquired diseases such as malignancies. 
The correction of 100 % of malignant cells is difficult to 
achieve in actively proliferating cells and the normaliza-
tion of the initial inducer mutation does not necessarily 
kill all malignant cells, and thus treatments are preferred 
to be designed for elimination of malignant cells by the 
therapeutic modalities based on gene therapy delivery tech-
nologies, not by simple mutation repair. Recent advance 
of CAR-T cell therapy, including its application to B cell 
Gene therapy and novel therapeutics applying gene ther-
apy-based techniques have experienced a drastic advance 
in the past 10 years. Clinically functional “gene therapies” 
are established now for certain diseases, and many other 
promising therapeutics have been developed, with such a 
trend being most noticeable in the field of hematological 
diseases.
Since most hereditary diseases are caused by genetic 
changes, fixing disease-related mutations has been a 
straight-forward and logical approach to treat hereditary 
diseases. However, as reported by Orkin-Motulsky Report 
in 1995 (http://osp.od.nih.gov/office-biotechnology-activ-
ities/orkin-motulsky-report), efficacy of gene delivery 
has been a large challenge for long span of time. Recent 
advances in “gene therapy” and “gene therapy-based 
approaches” have been quite substantial, which include 
delivery vectors, gene engineering technologies, applica-
tion to chimeric antigen receptor (CAR) T cell therapy, and 
oncolytic viruses. These advances have realized many of 
the unmet promises of gene therapy for genetic diseases. 
Furthermore, the application of gene therapy technolo-
gies to non-hereditary diseases such as malignancies has 
recently started to display positive outcomes, such as with 
CAR-T cell therapy and the oncolytic virus.
Interestingly, hematological diseases have been one of 
the main fields where many novel concepts, approaches, and 
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malignancies, is a lead example of such an approach. The 
development and application of CAR-T cells are reviewed 
by Drs. Davila and Sadelain. Gene delivery methodology 
has also been applied to malignancies from a variety of 
angles. Immuno-gene therapy (such as GVAX, GM-CSF-
producing whole tumor cell vaccine) has shown promising 
results, RNA interference has been actively tested, and sui-
cide gene-based regulation of GVHD has been tested for 
hematological malignancies. In addition, oncolytic virus 
is acquiring greater attention after oncolytic herpesvirus 
(T-VEC) was approved as a drug in 2015. These efforts are 
reviewed by Dr. Domingo-Musibay and Dr. Yamamoto.
As discussed in each review, gene therapy and gene ther-
apy-based therapeutic approaches have made significant 
advances in recent years. Hematology is one of the fields 
where rapid advance and broader clinical applications are 
expected, and some of the therapies are becoming relatively 
standard treatments already. In addition, many newly devel-
oped, promising therapies are waiting for clinical applica-
tion. We expect that the advance of therapeutic approaches 
based on gene therapy in the coming years will be even 
faster than the past 10 years. We hope these reviews pro-
vide quick insights to recent developments of gene therapy 
and new therapeutics arriving to clinics in the near future.
The guest editors thank all review authors for contribu-
tion, the Chief Editor, Dr. Kitamura, for this opportunity, 
and the Journal Office of International Journal of Hematol-
ogy for editorial work and patience.
